Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall SurvivalYu Sawada, Tetsuya Nakatsura, Tadatoshi Takayama et al.|Clinical Cancer Research|2012Cited by 299
HLA‐A2‐restricted CTL epitopes of a novel lung cancer‐associated cancer testis antigen, cell division cycle associated 1, can induce tumor‐reactive CTLMichiko Harao, Yasuharu Nishimura, Shinya Hirata et al.|International Journal of Cancer|2008Cited by 92
Proliferation Potential-Related Protein, an Ideal Esophageal Cancer Antigen for Immunotherapy, Identified Using Complementary DNA Microarray AnalysisYoshihiro Yoshitake, Yasuharu Nishimura, Tetsuya Nakatsura et al.|Clinical Cancer Research|2004Cited by 67
The forkhead box M1 transcription factor as a candidate of target for anti‐cancer immunotherapyKazunori Yokomine, Yasuharu Nishimura, Satoru Senju et al.|International Journal of Cancer|2009Cited by 40
Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell linesTetsuya Nakatsura|Oncology Reports|2011Cited by 32